Top

BMC Cancer

Published in:

Open Access 01-12-2021 | Gallbladder Cancer | Research article

Expression and functional characterization of INPP4B in gallbladder cancer patients and gallbladder cancer cells

Authors: Youliang Wu, Delong Meng, Xin Xu, Junjun Bao, Yexiang You, Yanjun Sun, Yongxiang Li, Dengqun Sun

Published in: BMC Cancer | Issue 1/2021

Abstract

Background

Inositol polyphosphate 4-phosphatase type II (INPP4B) is a negative regulator of the PI3K-Akt signalling pathway and plays a contradictory role in different types of cancers. However, the its biological role played by INPP4B in human gallbladder cancer (GBC) has not been elucidated. In this study, we investigated the expression, clinical significance and biological function of INPP4B in GBC patients and cell lines.

Methods

The INPP4B protein expression levels in gallbladder cancer tissues and normal gallbladder tissues were detected by immunohistochemistry, and the clinical significance of INPP4B was analysed. Knockdown and overexpression of INPP4B in GBC-SD and SGC-996 cells followed by cell proliferation, clonogenic, apoptosis detection, scratch wound-healing and transwell assays were used to identify INPP4B function in vitro.

Results

INPP4B was up-regulated in human GBC tissues compared with normal gallbladder tissues and was related to histopathological differentiation (p = 0.026). Here, we observed that INPP4B was highly expressed in high-moderately differentiated tumours compared with low-undifferentiated tumours (p = 0.022). Additionally, we found that INPP4B expression was not associated with overall survival of GBC patients (p = 0.071) and was not an independent prognostic factor. Furthermore, when we stratified the relationship between INPP4B expression and the prognosis of GBC based on histopathological differentiation, we found that INPP4B played a contradictory role in GBC progression depending on the degree of differentiation. In addition, INPP4B knockdown inhibited the proliferation, colony formation, migration and invasion in GBC cells, while INPP4B overexpression had the opposite effects in vitro, which indicates its role as an oncoprotein.

Conclusions

These findings suggested that INPP4B may play a dual role in the prognosis of GBC depending on the degree of differentiation and that INPP4B might act as an oncogene in gallbladder cancer cells.

Available only for authorised users

Wernberg JA, Lucarelli DD. Gallbladder cancer. Surg Clin North Am. 2014;94(2):343–60. https://doi.org/10.1016/j.suc.2014.01.009.CrossRefPubMed

Rawla P, Sunkara T, Thandra KC, Barsouk A. Epidemiology of gallbladder cancer. Clin Exp Hepatol. 2019;5(2):93–102. https://doi.org/10.5114/ceh.2019.85166.CrossRefPubMedPubMedCentral

Rakić M, Patrlj L, Kopljar M, Kliček R, Kolovrat M, Loncar B, et al. Gallbladder cancer. Hepatobiliary Surg Nutr. 2014;3(5):221–6. https://doi.org/10.3978/j.issn.2304-3881.2014.09.03.

Martini M, De Santis MC, Braccini L, et al. PI3K/AKT signaling pathway and cancer: an updated review. Ann Med. 2014;46(6):372–83. https://doi.org/10.3109/07853890.2014.912836.CrossRefPubMed

Fruman DA, Rommel C. PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov. 2014;13(2):140–56. https://doi.org/10.1038/nrd4204.CrossRefPubMedPubMedCentral

Zhao HF, Wang J, Shao W, Wu CP, Chen ZP, To SST, et al. Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development. Mol Cancer. 2017;16(1):100. https://doi.org/10.1186/s12943-017-0670-3.

Zhang L, Wu J, Ling MT, Zhao L, Zhao KN. The role of the PI3K/Akt/mTOR signalling pathway in human cancers induced by infection with human papillomaviruses. Mol Cancer. 2015;14(1):87. https://doi.org/10.1186/s12943-015-0361-x.CrossRefPubMedPubMedCentral

Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009;8(8):627–44. https://doi.org/10.1038/nrd2926.CrossRefPubMedPubMedCentral

Chen Y, Sun Z, Qi M, Wang X, Zhang W, Chen C, et al. INPP4B restrains cell proliferation and metastasis via regulation of the PI3K/AKT/SGK pathway. J Cell Mol Med. 2018;22(5):2935–43. https://doi.org/10.1111/jcmm.13595.

10.

Fedele CG, Ooms LM, Ho M, Vieusseux J, O'Toole SA, Millar EK, et al. Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers. Proc Natl Acad Sci U S A. 2010;107(51):22231–6. https://doi.org/10.1073/pnas.1015245107.

11.

Hodgson MC, Shao LJ, Frolov A, Li R, Peterson LE, Ayala G, et al. Decreased expression and androgen regulation of the tumor suppressor gene INPP4B in prostate cancer. Cancer Res. 2011;71(2):572–82. https://doi.org/10.1158/0008-5472.CAN-10-2314.

12.

Gewinner C, Wang ZC, Richardson A, Teruya-Feldstein J, Etemadmoghadam D, Bowtell D, et al. Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Cancer Cell. 2009;16(2):115–25. https://doi.org/10.1016/j.ccr.2009.06.006.

13.

Salmena L, Shaw P, Fans I, McLaughlin, Rosen B, Risch H, et al. Prognostic value of INPP4B protein immunohistochemistry in ovarian cancer. Eur J Gynaecol Oncol. 2015;36(3):260–7.

14.

Rynkiewicz NK, Fedele CG, Chiam K, Gupta R, Kench JG, Ooms LM, et al. INPP4B is highly expressed in prostate intermediate cells and its loss of expression in prostate carcinoma predicts for recurrence and poor long term survival. Prostate. 2015;75(1):92–102. https://doi.org/10.1002/pros.22895.

15.

Tang W, Yang L, Yang T, Liu M, Zhou Y, Lin J, et al. INPP4B inhibits cell proliferation, invasion and chemoresistance in human hepatocellular carcinoma. Onco Targets Ther. 2019;12:3491–507. https://doi.org/10.2147/OTT.S196832.

16.

Perez-Lorenzo R, Gill KZ, Shen CH, Zhao FX, Zheng B, Schulze HJ, et al. A tumor suppressor function for the lipid phosphatase INPP4B in melanocytic neoplasms. J Invest Dermatol. 2014;134(5):1359–68. https://doi.org/10.1038/jid.2013.511.

17.

Dzneladze I, He R, Woolley JF, Son MH, Sharobim MH, Greenberg SA, et al. INPP4B overexpression is associated with poor clinical outcome and therapy resistance in acute myeloid leukemia. Leukemia. 2015;29(7):1485–95. https://doi.org/10.1038/leu.2015.51.

18.

Guo ST, Chi MN, Yang RH, Guo XY, Zan LK, Wang CY, et al. INPP4B is an oncogenic regulator in human colon cancer. Oncogene. 2016;35(23):3049–61. https://doi.org/10.1038/onc.2015.361.

19.

Chi MN, Guo ST, Wilmott JS, Guo XY, Yan XG, Wang CY, et al. INPP4B is upregulated and functions as an oncogenic driver through SGK3 in a subset of melanomas. Oncotarget. 2015;6(37):39891–907. https://doi.org/10.18632/oncotarget.5359.

20.

Sung JY, Na K, Kim HS. Down-regulation of inositol polyphosphate 4-phosphatase type II expression in colorectal carcinoma. Anticancer Res. 2017;37(10):5525–31. https://doi.org/10.21873/anticanres.11984.CrossRefPubMed

21.

Wu Y, Yun D, Zhao Y, Wang Y, Sun R, Yan Q, et al. Down regulation of RNA binding motif, single-stranded interacting protein 3, along with up regulation of nuclear HIF1A correlates with poor prognosis in patients with gastric cancer. Oncotarget. 2017;8(1):1262–77. https://doi.org/10.18632/oncotarget.13605.

22.

Hammarsten P, Josefsson A, Thysell E, Lundholm M, Hägglöf C, Iglesias-Gato D, et al. Immunoreactivity for prostate specific antigen and Ki67 differentiates subgroups of prostate cancer related to outcome. Mod Pathol. 2019;32(9):1310–9. https://doi.org/10.1038/s41379-019-0260-6.

23.

Adan A, Kiraz Y, Baran Y. Cell proliferation and cytotoxicity assays. Curr Pharm Biotechnol. 2016;17(14):1213–21. https://doi.org/10.2174/1389201017666160808160513.CrossRefPubMed

24.

Zhai S, Liu Y, Lu X, Qian H, Tang X, Cheng X, et al. INPP4B as a prognostic and diagnostic marker regulates cell growth of pancreatic cancer via activating AKT. Onco Targets Ther. 2019;12:8287–99. https://doi.org/10.2147/OTT.S223221.

25.

Rafehi H, Orlowski C, Georgiadis GT, et al. Clonogenic assay: adherent cells. J Vis Exp. 2011;49:2573.

26.

Liu J, Wang X, Zhou G, Wang H, Xiang L, Cheng Y, et al. Cancerous inhibitor of protein phosphatase 2A is overexpressed in cervical cancer and upregulated by human papillomavirus 16 E7 oncoprotein. Gynecol Oncol. 2011;122(2):430–6. https://doi.org/10.1016/j.ygyno.2011.04.031.

27.

Duan Y, Hu L, Liu B, Yu B, Li J, Yan M, et al. Tumor suppressor miR-24 restrains gastric cancer progression by downregulating RegIV. Mol Cancer. 2014;13(1):127. https://doi.org/10.1186/1476-4598-13-127.

28.

Ding C, Tang W, Fan X, Wang X, Wu H, Xu H, et al. Overexpression of PEAK1 contributes to epithelial-mesenchymal transition and tumor metastasis in lung cancer through modulating ERK1/2 and JAK2 signaling. Cell Death Dis. 2018;9(8):802. https://doi.org/10.1038/s41419-018-0817-1.

29.

Ding C, Luo J, Li L, Li S, Yang L, Pan H, et al. Gab2 facilitates epithelial-to-mesenchymal transition via the MEK/ERK/MMP signaling in colorectal cancer. J Exp Clin Cancer Res. 2016;35(1):5. https://doi.org/10.1186/s13046-015-0280-0.

30.

Zhang F, Li J, Zhu J, Liu L, Zhu K, Cheng S, et al. IRF2-INPP4B-mediated autophagy suppresses apoptosis in acute myeloid leukemia cells. Biol Res. 2019;52(1):11. https://doi.org/10.1186/s40659-019-0218-7.

31.

Jin H, Yang L, Wang L, Yang Z, Zhan Q, Tao Y, et al. INPP4B promotes cell survival via SGK3 activation in NPM1-mutated leukemia. J Exp Clin Cancer Res. 2018;37(1):8. https://doi.org/10.1186/s13046-018-0675-9.

32.

Yang L, Ding C, Tang W, Yang T, Liu M, Wu H, et al. INPP4B exerts a dual function in the stemness of colorectal cancer stem-like cells through regulating Sox2 and Nanog expression. Carcinogenesis. 2020;41(1):78–90. https://doi.org/10.1093/carcin/bgz110.

33.

Chen H, Li H, Chen Q. INPP4B overexpression suppresses migration, invasion and angiogenesis of human prostate cancer cells. Clin Exp Pharmacol Physiol. 2017;44(6):700–8. https://doi.org/10.1111/1440-1681.12745.CrossRefPubMed

Title: Expression and functional characterization of INPP4B in gallbladder cancer patients and gallbladder cancer cells
Authors: Youliang Wu
Delong Meng
Xin Xu
Junjun Bao
Yexiang You
Yanjun Sun
Yongxiang Li
Dengqun Sun
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Gallbladder Cancer
Gallbladder Cancer
Published in: BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-021-08143-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Race disparities in mortality by breast cancer from 2000 to 2017 in São Paulo, Brazil: a population-based retrospective study

The genotypic and phenotypic impact of hypoxia microenvironment on glioblastoma cell lines

Risk factors for pegylated liposomal doxorubicin-induced moderate to severe hand-foot syndrome in breast cancer patients: assessment of baseline clinical parameters

Construction autophagy-related prognostic risk signature combined with clinicopathological validation analysis for survival prediction of kidney renal papillary cell carcinoma patients

A genomic-clinicopathologic Nomogram for the preoperative prediction of lymph node metastasis in gastric cancer

The evolution of the socio-cultural and religious characteristics of cancer patients in Morocco: case of the National Institute of Oncology Rabat

Keynote webinar | Spotlight on antibody–drug conjugates in cancer